ISSUE 91 I FEBRUARY 2020

EDS: treating

a medical zebra

A 'rare' condition that impacts connective tissue may be more common than previously thought, but how is it treated?

In association with

Ageing and drug development

Manufacturing drugs in space

Improving access to medicines

02/24/2024 00:26:53

01/24/2020 00:00:00

Go to article: Home | EDS: Treating a medical zebra Go to article: Scandinavian Health Ltd Go to article: Editorial Go to article: Emirates SkyCargo Go to article: Contents Go to article: Nolato Company Insight Go to article: Nolato Go to article: News Go to article: The pharma industry briefing Go to article: Subcuject Company Insight Go to article: Subcuject Go to article: Horizon 2020: a look back at flagship EU pharma projects Go to article: Sanofi Go to article: Sky high: should US drug prices fall in-line with the rest of the world?Go to article: Nipro Pharmapackaging Go to article: Q&A: talking drug quality with Valisure, the first analytical pharmacy Go to article: Nemera Go to article: What does ‘ageing’ mean when it comes to drug development? Go to article: Swiss WorldCargo Go to article: Manufacturing medicines in space: how astronauts will make their own drugs Go to article: Mimotopes Go to article: Aducanumab’s surprising revival: how an Alzheimer’s drug came back from the dead Go to article: Molnar Company Insight Go to article: Molnar-Institute Go to article: Ehlers-Danlos syndrome: The zebra in the room Go to article: Kugelmeiers Go to article: Stop ignoring the two billion: pharma’s role in expanding access to medicine Go to article: Skyepharma Go to article: IDMP: turning attention to patient benefits Go to article: Deals in brief powered by GlobalData Go to article: The key list powered by GlobalData Go to article: Events Go to article: Next issue